Noble launches its YpsoMate training device platform, elevates patient access
Noble unveiled today a new injectiontraining platform based on 1 mL and 2.25 mL YpsoMate devices to helpimprove patient onboarding and health outcomes.
Pharmaceuticals, Biotechnology and Life Sciences
Noble unveiled today a new injectiontraining platform based on 1 mL and 2.25 mL YpsoMate devices to helpimprove patient onboarding and health outcomes.
– First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018- – First-quarter 2019…
− In the United States, Company Completes Tenth Value-Based Agreement with Commercial Payers, and Achieves Confirmed Access to ONPATTRO for…
-Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support…
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia–(BUSINESS WIRE)–Date of conference call should read:…
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia–(BUSINESS WIRE)–Sproutly Canada, Inc. (CSE: SPR) (OTCQB:…
New facility focuses on specialized drug discovery technologies and discovery research across gastrointestinal and neuroscience therapeutic areas SAN DIEGO–(BUSINESS WIRE)–Takeda…
First-Quarter 2019 Worldwide Sales Were $10.8 Billion, an Increase of8%; Sales Increased 11% Excluding Negative Impact from ForeignExchange; Growth Driven by Oncology and Vaccines
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating…
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies…